National Institute for Korean Medicine Development Provides Customized Product Development Support to 14 Companies

Strengthening Full-Cycle Support from Clinical Trials and Commercialization to Regional Core Industry Linkage

The National Institute for Korean Medicine Development (President Koh Hoyoun) selected a total of 14 companies, including pharmaceutical companies and medical device manufacturers, through the "Customized Corporate Support Contest for Korean Medicine Product Development," which was promoted as part of the project to establish a full-cycle support system for the Korean medicine industry.

This project was established to promote the commercialization of promising technologies based on Korean medicine and to strengthen the industry's competitiveness through full-cycle support, from product development to clinical trials and demonstration.

The National Institute for Korean Medicine Development selected a total of 14 companies, including pharmaceutical firms and medical device manufacturers, through the "Customized Corporate Support Project for Korean Medicine Product Development," which was promoted as part of establishing a full-cycle support system for the Korean medicine industry. Provided by the National Institute for Korean Medicine Development

In particular, the initiative focuses on advancing technology in the field of Korean medicine and expanding its foundation for market entry, at a time when convergence with the bio and digital healthcare industries is accelerating.

The National Institute for Korean Medicine Development evaluated the feasibility of development plans, technological development capabilities, and commercialization potential. As a result, the institute selected a total of 14 projects, including: three herbal medicine formulations (AJ Bio Co., Ltd., Dr. BLab Co., Ltd., Panacura Co., Ltd.); two Korean medicine convergence projects (Healing Sound Co., Ltd., Medi K System); six application products utilizing Korean medicine (Human Cosmetic Co., Ltd., BNC Global Co., Ltd., Bionotech Co., Ltd., Haedam Co., Ltd., Garam of Nature, Haneulhosu); and three Korean medical device demonstration projects (Cort Co., Ltd., Orange Medical Co., Ltd., Jeongin Jeokbang Research Institute Co., Ltd.).

The selected companies will receive commercialization funding ranging from 50 million won to up to 80 million won per project.

Through this, the program will provide support for non-clinical and clinical trials for new drug approval, prototype advancement, clinical validation and suitability assessment for completed products or prototypes, and linkage support to regional core industries. These efforts are expected to lead to tangible industrial results, such as increased sales and job creation.

Meanwhile, the National Institute for Korean Medicine Development has been continuously promoting support projects for Korean medicine companies since 2021.

Notably, in 2025, the "Customized Corporate Support Project for Korean Medicine Product Development" produced remarkable outcomes as companies advanced beyond the development phase into commercialization.

Some of the supported companies obtained product approvals or completed medical device registrations, and achieved substantial results such as securing domestic and international distribution networks and expanding exports.

For example, Company A completed product approval in May 2025 for a liquid formulation for obesity and periodontal disease treatment, while Company B conducted multicenter clinical research on portable ultrasound diagnostic medical devices.

Company C developed products to improve blood circulation and cognitive function, entering domestic and overseas online distribution channels. Company D's customized scalp care products recorded export and local sales achievements, demonstrating examples of overseas market entry.

These achievements are considered examples that demonstrate the potential for Korean medicine to expand beyond traditional medicine into diverse industrial sectors, including digital healthcare, medical devices, and functional products.

Park Taesoon, Head of the Industrial Growth Support Center at the National Institute for Korean Medicine Development, said, "We hope that companies with excellent technologies in the Korean medicine field can take a leap into commercialization through this support project," adding, "We will continue to contribute to revitalizing the Korean medicine industry ecosystem by providing effective support that reflects on-the-ground needs."

This content was produced with the assistance of AI translation services.